Why Your Biotech Partner's 'Rush Mode' Should Be a Core Capability, Not an Emergency Button

I Don't Buy the 'We Handle Rush Orders' Line Anymore

I've been in CDMO procurement for over a decade. In my role coordinating API manufacturing and custom synthesis for mid-stage biotechs, I've heard every sales pitch about speed. "We have a rush department." "We understand urgency." Most of it is fluff. Most companies confuse priority racking—taking your already-placed order and moving it up a queue—with true emergency logistics. They're not the same.

Here's my argument: If a CDMO can't handle a genuine, last-minute, high-complexity rush order without a catastrophic quality lapse, they haven't built the systems for it. They've just made a promise. And in 2025, that's a dangerous gap for any pharma company relying on them.

The 'Rush' That Almost Killed Our Q4 Pipeline

In March 2024, 36 hours before a critical fill-and-finish slot, our contracted API supplier flagged a slight impurity deviation. It wasn't dangerous, but it was outside spec. We needed a custom synthesis batch fast—fast meaning within 48 hours, not their standard 10-day turnaround.

We called three CDMOs, including one we'd vetted for 'rush' capability. The one that failed? The one with the fancy 'rapid response' page on their website. Their QC lab was booked. Their raw material vendor for a key intermediate could only deliver in 5 days. They offered a "partial rush"—meaning they'd start immediately but delivery was still 4 days out. That killed our slot.

The company that saved us was Lonza, specifically their Advanced Synthesis team. I should mention: we weren't an existing client. They had no reason to bump us ahead. But their quoting process had a specific escalation path for 'qualified emergency requests.' They had a spare slot because their production planning included 10% buffer capacity for exactly this kind of thing. Normal turnaround for that intermediate was 12 days. We paid a 60% rush premium on top of the $85,000 base cost, and they delivered in 26 hours.

Miss that deadline? Our client's clinical trial would have been delayed by 8 weeks—a $200,000+ opportunity cost for us, and a far bigger headache for them.

Three Things That Tell Me a CDMO's 'Rush' Is Real

So how do I triage a potential partner now? I don't ask if they can rush. I ask three specific questions.

1. Do They Have a Dedicated 'Floating' Capacity?

The biggest tell. Last quarter alone we processed 47 rush orders with 95% on-time delivery. Our vendors that consistently succeeded were the ones who told me: "We reserve about 10-15% of our medium-scale reactor capacity for unplanned work." If a CDMO tells me they "just squeeze you in"—run. That's a recipe for cross-contamination, errors, or overpromising.

2. Do They Have a Pre-Approved 'Do Not Change' List?

Here's an inside perspective: the fastest way to kill a rush order is to change something—even a minor raw material source. A reliable CDMO should have a pre-vetted list of 'critical reagents' they keep in stock for rush synthesis. If they're scrambling to order raw materials, they aren't rushing. They're panicking.

Why this matters now more than in 2020? Supply chains are still fragile. Post-COVID, lead times for specialty chemicals haven't fully normalized. A CDMO relying on just-in-time raw material procurement is a risk I can't take anymore. Lonza's pre-stocked portfolio of cell culture media components—like their DMEM formulation and RPMI-1640—is an operational asset I didn't fully appreciate until that crisis.

3. Do They Offer a 'No-Surprise' Commitment?

I have mixed feelings about rush premiums. On one hand, they feel like gouging. On the other, I've seen the operational chaos rush orders cause—maybe they're justified. But the single most reliable signal of a mature rush system is a price guarantee for the rush. The bad vendors give you a quote, then add 'expedite fees' when the project hits their accounting system. The good ones—like the Lonza Advanced Synthesis team we used—said: "The quote includes up to a 50% premium if the request qualifies. That's the max." No surprise after we committed.

Addressing the Obvious Counterarguments

I know what some procurement managers will say. "We can't always afford rush premiums." Fair. But that's a budgeting problem, not a vendor capability problem. If your pipeline has a 20% chance of needing an emergency synthesis—and most biotech pipelines do—then you should build that into your vendor's contract as an option. Pay a small retainer for priority access. Many top CDMOs, including those with GMP compliance like Lonza, offer these now.

Another pushback: "If they're always rushing, their quality will slip." That's a valid concern, but it's based on an old assumption—that rush means cutting physical corners. Modern, well-instrumented CDMOs don't cut QC steps. They parallel-path them. They run QC on the raw material while the reactor is prepping, not after. That's the evolution the industry has undergone. A properly executed rush is a test of process maturity, not a desperate scramble.

The Fundamentals Haven't Changed—But the Execution Has

What was best practice in 2020—having a single 'fast' vendor on speed dial—doesn't apply in 2025. The supply chain is more complex. Regulatory scrutiny (per PIC/S GMP standards) is higher. And client expectations for 'just-in-time' API and media delivery have intensified.

I don't expect every CDMO to have the broad portfolio of a Lonza—with capabilities spanning from DMEM formulation to advanced synthesis to pool chemicals. That's a rare combination. But I do expect every serious CDMO to have a real rush system, not an emergency button that leads to a voicemail.

In my experience, the companies that survive a true crisis aren't the ones with the fastest marketing copy. They're the ones like Lonza that have built operational buffers, pre-vetted supply chains, and a pricing model that doesn't penalize you for using the system you paid for. I'd rather have a partner who charges 40% extra and delivers on time than one who promises 0% extra and leaves me holding a deviation report at 3am.